CLARITY MEDICAL (01406) announced that the Group has continued to deliver high-quality ophthalmic medical services over the past several months. Following the official launch of the SILK refractive surgery platform in partnership with Johnson & Johnson in November 2025, the Company has become the only ophthalmic center in Hong Kong offering a comprehensive portfolio of advanced refractive treatment options—including LASIK, SMILE, SMILE Pro, SILKTM, and ICL—further solidifying its technological leadership in the Hong Kong ophthalmic market. The Group's operational performance has remained robust. After a period of softer performance in the months covered by the previous update, operational metrics gradually recovered towards the end of 2025, with patient visits, new patient bookings, and surgical procedure volumes for December reaching or exceeding levels seen in the same period over the past two years. The Group led the Hong Kong market in ICL procedure volume for the year 2025, achieving the top position in the industry for the third consecutive year. As detailed in the two quarterly updates dated July 14, 2025, and October 14, 2025, persistent allegations made by certain former directors against the Company and its management have resulted in significant professional fees for the Group (exceeding HKD 15 million to date), creating a substantial financial burden—resources that could otherwise have been allocated to business development and enhancing shareholder returns. The Group is committed to efficiently and systematically concluding the related investigation, expediting the resumption of trading in the Company's shares, and allowing management to refocus on executing its long-term strategic priorities. The latest resumption guidance for the Company, as of the date of this announcement, is as follows: (i) guidance concerning the investigation of the allegations and remedial measures; (ii) integrity guidance; (iii) internal control guidance; (iv) corporate governance guidance; (v) disclosure guidance; (vi) financial reporting guidance; and (vii) Rule 13.24 guidance.